300 related articles for article (PubMed ID: 26084268)
1. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
Ni Z; Zhang TC
J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
[TBL] [Abstract][Full Text] [Related]
2. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
4. Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors.
Nagasundaram N; Wilson Alphonse CR; Samuel Gnana PV; Rajaretinam RK
J Cell Biochem; 2017 Oct; 118(10):3462-3471. PubMed ID: 28332225
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI
Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.
Ni Z; Wang X; Zhang T; Jin RZ
Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703
[TBL] [Abstract][Full Text] [Related]
7. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
[TBL] [Abstract][Full Text] [Related]
9. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
10. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
11. Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R.
Mathi GR; Kang CH; Lee HK; Achary R; Lee HY; Lee JY; Ha JD; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
Eur J Med Chem; 2017 Jan; 126():536-549. PubMed ID: 27915169
[TBL] [Abstract][Full Text] [Related]
12. Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations.
He MY; Li WK; Meiler J; Zheng QC; Zhang HX
Biopolymers; 2019 Feb; 110(2):e23257. PubMed ID: 30664251
[TBL] [Abstract][Full Text] [Related]
13. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.
Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558
[TBL] [Abstract][Full Text] [Related]
14. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
15. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
16. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
[TBL] [Abstract][Full Text] [Related]
17. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
[TBL] [Abstract][Full Text] [Related]
18. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
Ai X; Shen S; Shen L; Lu S
Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
[TBL] [Abstract][Full Text] [Related]
19. Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.
Sun H; Li Y; Li D; Hou T
J Chem Inf Model; 2013 Sep; 53(9):2376-89. PubMed ID: 23952683
[TBL] [Abstract][Full Text] [Related]
20. Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs.
Li J; Liu W; Luo H; Bao J
J Mol Model; 2016 Sep; 22(9):231. PubMed ID: 27585676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
